ZA917610B - Xanthine derivatives - Google Patents

Xanthine derivatives

Info

Publication number
ZA917610B
ZA917610B ZA917610A ZA917610A ZA917610B ZA 917610 B ZA917610 B ZA 917610B ZA 917610 A ZA917610 A ZA 917610A ZA 917610 A ZA917610 A ZA 917610A ZA 917610 B ZA917610 B ZA 917610B
Authority
ZA
South Africa
Prior art keywords
xanthine derivatives
xanthine
derivatives
Prior art date
Application number
ZA917610A
Other languages
English (en)
Inventor
Derek Richard Buckle
Richard Buckle Derek
David Glynn Smith
Glynn Smith David
Ashley Edward Fenwick
Edward Fenwick Ashley
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of ZA917610B publication Critical patent/ZA917610B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA917610A 1990-09-26 1991-09-24 Xanthine derivatives ZA917610B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909020959A GB9020959D0 (en) 1990-09-26 1990-09-26 Novel compounds

Publications (1)

Publication Number Publication Date
ZA917610B true ZA917610B (en) 1992-09-30

Family

ID=10682788

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA917610A ZA917610B (en) 1990-09-26 1991-09-24 Xanthine derivatives

Country Status (12)

Country Link
EP (1) EP0550570A1 (fr)
JP (1) JPH06501251A (fr)
KR (1) KR930702351A (fr)
AU (1) AU653364B2 (fr)
CA (1) CA2092430A1 (fr)
GB (1) GB9020959D0 (fr)
IE (1) IE913350A1 (fr)
MX (1) MX9101237A (fr)
NZ (1) NZ239921A (fr)
PT (1) PT99062A (fr)
WO (1) WO1992005175A1 (fr)
ZA (1) ZA917610B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5409934A (en) * 1990-12-21 1995-04-25 Smith; David G. Xanthine derivatives
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
EP0814809B1 (fr) * 1994-12-13 2003-08-13 Euroceltique S.A. Aryle thioxanthines
WO1996036638A1 (fr) * 1995-05-19 1996-11-21 Chiroscience Limited Xanthines et leur utilisation therapeutique
AR015190A1 (es) * 1997-10-23 2001-04-18 Smithkline Beecham Corp Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento
RU2003103103A (ru) * 2000-07-04 2004-08-20 Ново Нордиск А/С (DK) Гетероциклические соединения, которые являются ингибиторами фермента dpp-iv
EP1301187B1 (fr) * 2000-07-04 2005-07-06 Novo Nordisk A/S Purine-2,6-diones comme inhibiteurs des enzymes dipeptidyl-peptidase iv (dpp-iv)
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
AR036674A1 (es) 2001-08-28 2004-09-29 Schering Corp Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos
EP1442042A1 (fr) 2001-11-09 2004-08-04 Schering Corporation Inhibiteurs de la phosphodiesterase v de derives polycycliques de guanine
EP1719772A1 (fr) 2002-05-31 2006-11-08 Schering Corporation Procédé de préparation d'inhibiteurs de la phosphodiesterase v de la xanthine et leur précurseurs
AU2003231805A1 (en) 2002-06-17 2004-02-09 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ES2284056T3 (es) 2003-07-31 2007-11-01 Schering Corporation Metabolito de inhibidor de fosfodiesterasa 5 de xantina y sus derivados, utiles para el tratamiento de la disfuncion erectil.
WO2005058898A2 (fr) * 2003-12-16 2005-06-30 Ranbaxy Laboratories Limited Inhibiteurs de la phosphodiesterase
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004037554A1 (de) 2004-08-03 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkylthio-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039507A1 (de) 2004-08-14 2006-03-02 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkoxi-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
NO347644B1 (no) 2006-05-04 2024-02-12 Boehringer Ingelheim Int Polymorfer
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (fr) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Formes salines de 1-[(4-methyl-quinazoline-2-yl)methyl]-3-methyl-7-(2-butyne-1-yl)-8(3-(r)-amino-piperidine-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EA030121B1 (ru) 2011-07-15 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные хиназолины, их получение и их применение в фармацевтических композициях
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2015128453A1 (fr) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Utilisation médicale d'un inhibiteur de dpp-4
EP4233840A3 (fr) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinaisons de linagliptine et de metformine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988005775A1 (fr) * 1987-01-30 1988-08-11 Sandoz-Erfindungen Verwaltungsgesellschaft M.B.H. Nouveaux derives de xanthine
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
WO1992007852A1 (fr) * 1990-10-25 1992-05-14 G.D. Searle & Co. Composes de xanthine de biphenylalkyle pour le traitement de troubles cardiovasculaires

Also Published As

Publication number Publication date
AU653364B2 (en) 1994-09-29
JPH06501251A (ja) 1994-02-10
CA2092430A1 (fr) 1992-03-27
GB9020959D0 (en) 1990-11-07
AU8541391A (en) 1992-04-15
EP0550570A1 (fr) 1993-07-14
PT99062A (pt) 1992-08-31
NZ239921A (en) 1993-12-23
KR930702351A (ko) 1993-09-08
WO1992005175A1 (fr) 1992-04-02
MX9101237A (es) 1992-05-04
IE913350A1 (en) 1992-04-08

Similar Documents

Publication Publication Date Title
ZA917610B (en) Xanthine derivatives
EP0440950A3 (en) Halogenallyl-azolyl derivatives
HU912356D0 (en) Rapacmycine derivatives
ZA916098B (en) Oxazolidinodione derivatives
EP0470466A3 (en) Halogenalkyl-azolyl derivatives
ZA914484B (en) Azolyl-propanol derivatives
ZA9172B (en) Azaoxindole derivatives
HRP930485A2 (en) Hiv-inhibiting benzenacetamide derivatives
IL99576A0 (en) Triazacyclohexane derivatives
EP0438690A3 (en) Substituted pyrazolin derivatives
ZA916254B (en) Halogenoalkyl-azolyl derivatives
EP0485984A3 (en) Diarylmethoxypiperidine derivatives
ZA914204B (en) Pyridinylpiperazine derivatives
ZA915418B (en) Purine derivatives
GB9007569D0 (en) Carbo-nucleoside derivatives
EP0440949A3 (en) Halogenallyl-azolyl derivatives
ZA914675B (en) 5-isothiazolamine derivatives
EP0556778A3 (en) Xanthine derivatives
EP0453883A3 (en) 2-amino-4-trichloropyridine derivatives
ZA915878B (en) Carboxymethylcyclopropane derivatives
GB2249094B (en) Hetero-imidazodiazepine derivatives
EP0449346A3 (en) 4-piperidinyl-ergoline derivatives
EG19474A (en) Nitroenamine derivatives
EG19362A (en) Azoaxindole derivatives
IL97680A0 (en) Nitroenamine derivatives